ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Wei NieZhi-Jie WangKai ZhangBing LiYi-Ran CaiFeng-Cai WenDing ZhangYue-Zong BaiXue-Yan ZhangShu-Yuan WangLei ChengHua ZhongLi LiuJie WangBao-Hui HanPublished in: BMC medicine (2022)
Our study indicated that ctDNA-adjusted bTMB might predict OS benefit in NSCLC patients receiving ICIs. The potential of ctDNA-adjusted bTMB as a noninvasive predictor for immunotherapy should be confirmed in future studies.